Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update a 2007 Report: Comparative Effect
2 Angebote vergleichen
Bester Preis: € 32,96 (vom 15.04.2017)1
Treatment to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
EN NWISBN: 9781484077375 bzw. 1484077377, in Englisch, Createspace Independent Publishing Platform, neu.
Lieferung aus: Vereinigtes Königreich Großbritannien und Nordirland, in-stock.
Osteoporosis is a systemic skeletal disease characterized by decreasing bone mass and microarchitectural deterioration of bone tissue, with consequent increases in bone fragility and susceptibility to fracture. In addition to fractures, the clinical complications of osteoporosis include disability and chronic pain. Approximately 52 million people in the United States are affected by osteoporosis or low bone density. It is especially common in postmenopausal women, but one in five men will experience an osteoporosis-related fracture at some point in his lifetime. The economic burden of osteoporosis is large and growing: the most recent estimate of U.S. annual costs due to fractures alone have been nearly $20 billion. A recent projection of the burden and costs of incident osteoporosis-related fractures in the United States from 2005 to 2025 estimates more than 2 million fractures in 2010, with direct medical costs of more than $18 billion (more than 25 percent attributable to men). Although the bulk of these costs are incurred by individuals 65 and older, direct costs and productivity loss among working women under 65 are considerable. Since the release of the original report, several of the bisphosphonates have become available in new, less frequently administered, forms, and a new biological agent, denosumab, is now available. In addition, new data have been released on adverse events associated with bisphosphonates. The update search identified new data on effectiveness and adverse effects. Thus the following questions guided the current report. Key Question 1: What are the comparative benefits in fracture risk reduction among the following therapeutic modalities for low bone density: Bisphosphonate medications, specifically: Alendronate (Fosamax®, oral), Risedronate (Actonel®; oral once-a-week), Ibandronate (Boniva®), Zoledronic acid (Reclast®IV); Denosumab (Prolia®); Menopausal estrogen therapy for women (numerous brands and routes of administration); .
Osteoporosis is a systemic skeletal disease characterized by decreasing bone mass and microarchitectural deterioration of bone tissue, with consequent increases in bone fragility and susceptibility to fracture. In addition to fractures, the clinical complications of osteoporosis include disability and chronic pain. Approximately 52 million people in the United States are affected by osteoporosis or low bone density. It is especially common in postmenopausal women, but one in five men will experience an osteoporosis-related fracture at some point in his lifetime. The economic burden of osteoporosis is large and growing: the most recent estimate of U.S. annual costs due to fractures alone have been nearly $20 billion. A recent projection of the burden and costs of incident osteoporosis-related fractures in the United States from 2005 to 2025 estimates more than 2 million fractures in 2010, with direct medical costs of more than $18 billion (more than 25 percent attributable to men). Although the bulk of these costs are incurred by individuals 65 and older, direct costs and productivity loss among working women under 65 are considerable. Since the release of the original report, several of the bisphosphonates have become available in new, less frequently administered, forms, and a new biological agent, denosumab, is now available. In addition, new data have been released on adverse events associated with bisphosphonates. The update search identified new data on effectiveness and adverse effects. Thus the following questions guided the current report. Key Question 1: What are the comparative benefits in fracture risk reduction among the following therapeutic modalities for low bone density: Bisphosphonate medications, specifically: Alendronate (Fosamax®, oral), Risedronate (Actonel®; oral once-a-week), Ibandronate (Boniva®), Zoledronic acid (Reclast®IV); Denosumab (Prolia®); Menopausal estrogen therapy for women (numerous brands and routes of administration); .
2
Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update a 2007 Report: Comparative Effect
EN PB NWISBN: 9781484077375 bzw. 1484077377, in Englisch, CreateSpace Publishing, Taschenbuch, neu.
Lieferung aus: Vereinigte Staaten von Amerika, In Stock.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Lade…